DoximityBSP:D2OC34 62 EBITDA Margin % is 19.92% as of Mar. 2026, which is 40% below its 10-year median of 33.42. GuruFocus rates BSP:D2OC34 with a GF Score™ of 62/100 and a GF Value™ of R$39.99 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Doximity ranks better than 94.16% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Doximity's EBITDA for the
three
months ended in Mar. 2026 was R$151 Mil. Doximity's Revenue for the
three
months ended in Mar. 2026 was R$760 Mil. Therefore, Doximity's EBITDA margin for the quarter that ended in Mar. 2026 was 19.92%.
Doximity (BSP:D2OC34) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Doximity EBITDA Margin % Related Terms
Doximity EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Doximity's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:D2OC34 vs WAY, TXG, HNGE: EBITDA Margin % Comparison
For the Health Information Services subindustry, Doximity's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doximity EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Doximity's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Doximity's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Doximity (BSP:D2OC34) has a EBITDA Margin % of 19.92% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Doximity and its competitors. This is 40% below median its historical median of 33.42. Over the past decade, Doximity's EBITDA Margin % has ranged from 8.72 to 42.21. According to the industry distribution chart, Doximity ranks #39 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 5.8%.
Is Doximity's EBITDA Margin % too high?
Doximity's current EBITDA Margin % of 19.92% is 40% below median its 10-year median of 33.42. Over the past 10 years, this metric has ranged from a low of 8.72 to a high of 42.21. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Doximity's value of 19.92% is 95.1% above this industry median. Based on the distribution chart, Doximity ranks #39 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Doximity has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Doximity's EBITDA Margin % compare to WAY and TXG?
According to the Healthcare Providers & Services industry distribution chart, Doximity ranks #39 out of 668 companies for EBITDA Margin %. This places Doximity in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Doximity's value of 19.92% is 95.1% above this benchmark. Historically, Doximity's own EBITDA Margin % has ranged from 8.72 to 42.21 over the past decade. While the company's 10-year median is 33.42 vs. the industry median of 10.21, Doximity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Doximity's current EBITDA Margin % of 19.92% is 95.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Doximity and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Doximity's current EBITDA Margin % is 19.92%, which is 40% below median its own 10-year median of 33.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doximity stock overvalued right now?
Based on GuruFocus' analysis, Doximity (BSP:D2OC34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$39.99, compared to a current price of R$17.14 — trading 57.1% below its estimated fair value. The current EBITDA Margin % is 19.92%, which is 40% below median its 10-year median of 33.42 and 95.1% above the Healthcare Providers & Services industry median of 10.21. Doximity's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Doximity (BSP:D2OC34), the current EBITDA Margin % is 19.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doximity (BSP:D2OC34) Overvalued in 2026?
Based on GuruFocus' analysis, Doximity stock appears to be undervalued.
The current stock price of R$17.14 is trading 57.1% below its estimated GF Value™ of R$39.99.
GuruFocus considers Doximity to be Significantly Undervalued.
Key valuation signals for BSP:D2OC34:
EBITDA Margin %: 19.92% (40% below median its 10-year median of 33.42)
GF Value™: R$39.99 vs. price of R$17.14 (57.1% below fair value)
Industry Position: 95.1% above the Healthcare Providers & Services median (#39 of 668)
No single metric tells the full story. See the BSP:D2OC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
62GF Score
Get the complete analysis for BSP:D2OC34
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:D2OC34 has been successfully added to your 
